Trodelvy
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
Anika Sharma
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Gilead’s $3B Oncology Milestone: Trodelvy, Tecartus and Yescarta Lead the Way in 2023
SG Tylor
Gilead Sciences has been making significant strides in the oncology space, fueled by the success of its rising star drug, ...
Trodelvy: The New Hope for Breast Cancer Patients
SG Tylor
Trodelvy is a brand name for sacituzumab govitecan-hziy, a new type of drug that combines an antibody with a chemotherapy ...
Gilead’s Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer Receives European Commission Approval
SG Tylor
Source – Gilead Gilead Sciences, has received approval from the European Commission (EC) for the use of Trodelvy (sacituzumab govitecan) ...
